Abstract
It has been demonstrated that Botulinum toxin type A (BoNT-A), in addition of inhibiting the release of acetylcholine at the neuromuscular junction, has a peripheral antinociceptive effect that also reduces the release of sensitive neurotransmitters such as substance P, glutamate, calcitonine gene related peptide and the pro-inflammatory cytokine IL-1².(1) Moreover, current data indicate …